Pathology Highlights of the Year 2022 – Breast Cancer

One of the highlights of this year’s congresses was the presentation of the results of the study by Dr. Blaye et al. on an immunological signature to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemo-therapy (NACT) (1) .